Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 23, 2023 06:51 ET | Source: Fortune Business Insights

Tardive Dyskinesia Therapeutics Market Size to Surpass USD 5.09 billion by 2030, exhibiting a CAGR of 9.1%

Pune, India, May 23, 2023 (GLOBE NEWSWIRE) -- According to Fortune Business Insights, the tardive dyskinesia therapeutics market size was valued at USD 2.33 billion in 2022 and is projected to grow...
December 29, 2022 07:08 ET | Source: Research and Markets

Autism Spectrum Disorder Treatment Global Market Report 2022: Sector to Grow by 6.47% Annually Through 2033

Dublin, Dec. 29, 2022 (GLOBE NEWSWIRE) -- The "Autism Spectrum Disorder Treatment Market by Treatment, Application, Distribution Channel, and by Region - Global Forecast to 2022-2033" report has...
August 29, 2022 13:00 ET | Source: DelveInsight Business Research LLP

Global Dyskinesia Pipeline Insight | Clinical Trials Research Report 2022 by DelveInsight

New York, USA, Aug. 29, 2022 (GLOBE NEWSWIRE) -- Global Dyskinesia Pipeline Insight | Clinical Trials Research Report 2022 by DelveInsight Dyskinesia Pipeline constitutes 40+ key companies...
November 22, 2021 10:00 ET | Source: Adhera Therapeutics, Inc.

Adhera Therapeutics Receives Notice of Allowance for New Canadian Patent Covering MLR-1019 for Dyskinesia and Related Disorders

Baton Rouge, LA, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCPK: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, is pleased to announce that a new...
April 27, 2021 06:28 ET | Source: Research and Markets

Global Parkinson's Disease Drug Forecast Report 2021-2029, Featuring Teva, Roche, Prothena, UCB, AbbVie and Norvartis

Dublin, April 27, 2021 (GLOBE NEWSWIRE) -- The "Parkinson's Disease - Global Drug Forecast and Market Analysis to 2029" report has been added to ResearchAndMarkets.com's offering. The global PD...
November 01, 2018 16:01 ET | Source: Adamas Pharmaceuticals, Inc.

Adamas Reports Third Quarter 2018 Financial Results

GOCOVRI™ (amantadine) extended release capsules sales increased to $10.6 million for the third quarter, with ~4,740 fulfilled prescriptions EMERYVILLE, Calif., Nov. 01, 2018 (GLOBE NEWSWIRE) --...
October 04, 2018 09:00 ET | Source: Adamas Pharmaceuticals, Inc.

Adamas Announces Publication of Data Demonstrating Dyskinesia’s Impact on Activities of Daily Living in People with Parkinson’s Disease

EMERYVILLE, Calif., Oct. 04, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous...
August 02, 2018 16:01 ET | Source: Adamas Pharmaceuticals, Inc.

Adamas Reports Second Quarter 2018 Financial Results

- GOCOVRI™ (amantadine) extended release capsules product sales reached $7.6 million for the second quarter - EMERYVILLE, Calif., Aug. 02, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc....
August 01, 2018 09:00 ET | Source: Adamas Pharmaceuticals, Inc.

Adamas Pharmaceuticals Launches “Dyskinesia Is A Jerk™,” a Campaign to Raise Awareness and Highlight the Impact of Parkinson’s Disease Dyskinesia

- Despite significant impact on daily life and the ability to treat primary symptoms of Parkinson’s disease dyskinesia (uncontrolled jerking or twisting movements), symptoms are often not recognized...
June 22, 2018 09:12 ET | Source: Adamas Pharmaceuticals, Inc.

Adamas Presents New Data Analysis Demonstrating that GOCOVRI™ Reduces Transitions between Dyskinesia and OFF Episodes Throughout the Day

EMERYVILLE, Calif., June 22, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced the presentation of new data analysis of GOCOVRI™ (amantadine) extended release...